Octreotide Acetate Recall; New Metabolic Surgery Guidelines; Insulin Murder Charges

The FDA announced a voluntary recall of one lot of Mylan's octreotide acetate injection due to possible glass particles in the syringes.

Could the nationwide semaglutide (Wegovy, Ozempic) shortage be due to its growing popularity across social media? (CBS News)

The American Society for Metabolic and Bariatric Surgery teamed up with the International Federation for the Surgery of Obesity and Metabolic Disorders to issue new clinical practice guidelines for metabolic surgery, intended to replace the NIH's 1991 consensus statement on the topic. (Surgery for Obesity and Related Diseases)

A 32-person trial of premenopausal women with hypoactive sexual desire disorder found that a 75-minute intravenous infusion of kisspeptin-54 modulated sexual and attraction brain processing. (JAMA Network Open)

The FDA accepted Ascendis Pharma's new drug application for priority review of its adult hypoparathyroidism treatment palopegteriparatide (TransCon PTH) and set a PDUFA target action date of April 30, 2023.

In other agency news, Rhythm Pharmaceuticals announced that the FDA granted breakthrough therapy designation to the company's MC4R agonist setmelanotide (Imcivree) for the treatment of hypothalamic obesity. The product already holds indications for obesity due to proopiomelanocortin, proprotein convertase subtilisin/kexin type 1 or leptin receptor deficiency, and Bardet-Biedl syndrome.

A former nurse at Atrium Health Wake Forest Baptist Medical Center in North Carolina has been charged with murdering multiple patients by administering lethal doses of insulin. (WRAL)

Gonadotropin-releasing hormone analogue (GnRHa) use during puberty wasn't tied to increased future gender-affirming hormone (GAH) use in transgender and gender-diverse kids, suggesting that "clinicians can offer the benefits of GnRHa treatment without concern for increasing rates of future GAH use." (JAMA Network Open)

Comment